Therapy of follicular lymphoma

被引：2

作者：

Buske C. ^{[1
,2
]}

Unterhalt M. ^{[1
]}

Hiddeman W. ^{[1
]}

机构：

[1] Med. Klinik und Poliklinik III, Klinikum der Universität München-Großhadern

[2] Med. Klinik und Poliklinik III, Klinikum der Universität München-Großhadern, München 81377

来源：

Der Internist | 2007年 / 48卷 / 4期

关键词：

Autologous stem cell transplantation; Chemotherapy; Follicular lymphoma; Radioimmunotherapy; Rituximab;

D O I：

10.1007/s00108-007-1804-2

中图分类号：

学科分类号：

摘要：

The treatment options for patients with follicular lymphoma have substantially improved in the last years, in particular with the development of innovative, antibody-based therapeutic strategies. Thus, the anti-CD20 antibody rituximab is one of the cornerstones in the therapy of follicular lymphoma today. It is used in combination with chemotherapy or as a single agent therapy for remission induction and as maintenance therapy. Encouraging results were also reported from monoclonal anti-CD20 antibodies, which are conjugated to radionuclides and exploit the high radiosensitivity of lymphomas. An example for this is the anti-CD20 antibody ibritumomab tiuxetan, which is coupled to 90Yttrium and shows comparable activity to rituximab. Current trials are underway testing whether, for example, the sequential application of a rituximab/chemotherapy induction, myeloablative consolidation therapy followed by autologous stem cell transplantation and rituximab maintenance further improves the therapeutic outcome in follicular lymphoma, or even has curative potential in a subgroup of patients with this disease. © 2007 Springer Medizin Verlag.

引用

页码：372 / 381

页数：9

共 16 条

[1]

Buske C., Hiddemann W., Rituximab maintenance therapy in indolent NHL: A clinical review, Leuk Res, 30, (2006)

[2]

Buske C., Hoster E., Dreyling M., Et al., The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome, Blood, 108, pp. 1504-1508, (2006)

[3]

Deconinck E., Foussard C., Milpied N., Et al., High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS, Blood, 105, pp. 3817-3823, (2005)

[4]

Dreyling M., Forstpointner R., Ludwig W.D., Et al., Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma-follow-up of a randomized trial of the German Low Grade Lymphoma Study Group (GLSG), J Clin Oncol, 23, (2005)

[5]

Dreyling M., Trumper L., von Schilling C., Et al., Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma-role of radioimmunotherapy, Ann Hematol, 86, pp. 81-87, (2006)

[6]

Forstpointner R., Unterhalt M., Dreyling M., Et al., Maintenance therapy with rituximab leads to a significant prolongation of response..., Blood, 108, pp. 4003-4008, (2006)

[7]

Ghielmini M., Schmitz S.F., Cogliatti S.B., Et al., Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule, Blood, 103, pp. 4416-4423, (2004)

[8]

Herold M., Haas A., Srock S., Et al., Addition of rituximab to first-line MCP (mitoxantrone, clorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma: 4 year follow-up results of a phase III trial of the East German Study Group Hematology and Oncology (OSHO# 39), Blood, 108, (2006)

[9]

Hiddemann W., Kneba M., Dreyling M., Et al., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, 106, pp. 3725-3732, (2005)

[10]

Hochster H.S., Weller E., Gascoyne R.D., Et al., Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Session, Blood, 106, (2005)

← 1 2 →